Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Rectal ulcer and pseudomalignant epithelial changes after prostate seed brachytherapy: A rare complication with a diagnostic pitfall.

Lee H, Sheuka N, El-Kadi O, Murray BP, Fisher HA, Kallakury BVS, Lee EC, Boguniewicz A, Jennings TA.

Ann Diagn Pathol. 2018 Jun;34:131-134. doi: 10.1016/j.anndiagpath.2018.03.011. Epub 2018 Apr 4.

PMID:
29661719
2.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.

Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V, Pal SK.

Cancer. 2016 Mar 1;122(5):702-11. doi: 10.1002/cncr.29826. Epub 2015 Dec 9.

3.

Localized lymphedema (elephantiasis): a case series and review of the literature.

Lu S, Tran TA, Jones DM, Meyer DR, Ross JS, Fisher HA, Carlson JA.

J Cutan Pathol. 2009 Jan;36(1):1-20. doi: 10.1111/j.1600-0560.2008.00990.x. Epub 2008 Jun 17. Erratum in: J Cutan Pathol. 2009 Apr;36(4):502.

PMID:
18564285
4.

Tissue-marking scheme for a cost-effective extended prostate biopsy protocol.

Firoozi F, Nazeer T, Fisher HA, Kaufman RP Jr, White MD, Mian BM.

Urol Oncol. 2009 Jan-Feb;27(1):21-5. doi: 10.1016/j.urolonc.2007.09.002. Epub 2008 Jan 14.

PMID:
18367125
5.

PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.

Bratslavsky G, Fisher HA, Kaufman RP Jr, Voskoboynik D, Nazeer T, Mian BM.

Urol Oncol. 2008 Mar-Apr;26(2):166-70. doi: 10.1016/j.urolonc.2007.05.030. Epub 2007 Nov 26.

PMID:
18312936
6.

Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas.

Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS.

Hum Pathol. 2007 Apr;38(4):564-9. Epub 2007 Feb 15.

PMID:
17306334
7.

Management of small renal cancers: choices for the patient and physician.

Fisher HA.

J Urol. 2006 Nov;176(5):1907-8. No abstract available.

PMID:
17070207
8.

Bladder cancer: in search of the right operation for the right patient.

Fisher HA.

J Urol. 2006 Jun;175(6):1987-8. No abstract available.

PMID:
16697781
9.

Role of prostate biopsy schemes in accurate prediction of Gleason scores.

Mian BM, Lehr DJ, Moore CK, Fisher HA, Kaufman RP Jr, Ross JS, Jennings TA, Nazeer T.

Urology. 2006 Feb;67(2):379-83.

PMID:
16461089
10.

Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas.

Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS.

Hum Pathol. 2005 Nov;36(11):1204-9.

PMID:
16260274
11.

Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era.

Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM.

J Urol. 2005 Jan;173(1):70-2.

PMID:
15592031
12.

Prognostic factors in prostate cancer.

Ross JS, Jennings TA, Nazeer T, Sheehan CE, Fisher HA, Kauffman RA, Anwar S, Kallakury BV.

Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100. Review.

PMID:
15298146
13.

Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence.

Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Stringer B.

Clin Cancer Res. 2004 Apr 1;10(7):2466-72.

14.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV.

Clin Cancer Res. 2003 Dec 15;9(17):6357-62.

15.

Survivin and Bcl-2 expression in prostatic adenocarcinomas.

Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS.

Arch Pathol Lab Med. 2004 Jan;128(1):39-43.

PMID:
14692814
16.

Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.

Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV.

Mod Pathol. 2003 Mar;16(3):198-205.

18.

Prognostic markers in prostate cancer.

Ross JS, Sheehan CE, Fisher HA, Kauffman RA, Dolen EM, Kallakury BV.

Expert Rev Mol Diagn. 2002 Mar;2(2):129-42. Review.

PMID:
11962333
19.

Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas.

Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP Jr, Ross JS.

Cancer. 2001 Dec 1;92(11):2786-95.

PMID:
11753952
20.
21.

Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer.

Ross JS, Sheehan CE, Ambros RA, Nazeer T, Jennings TA, Kaufman RP Jr, Fisher HA, Rifkin MD, Kallakury BV.

Am J Surg Pathol. 1999 Mar;23(3):296-301.

PMID:
10078920
22.

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.

Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ, Ross JS.

J Clin Oncol. 1998 Apr;16(4):1302-9.

PMID:
9552030
23.

Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy.

Groudine SB, Fisher HA, Kaufman RP Jr, Patel MK, Wilkins LJ, Mehta SA, Lumb PD.

Anesth Analg. 1998 Feb;86(2):235-9.

PMID:
9459225
24.

The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.

Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Ross JS.

Cancer. 1997 Aug 15;80(4):753-63.

PMID:
9264360
25.

Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas.

Kallakury BV, Brien TP, Lowry CV, Muraca PJ, Fisher HA, Kaufman RP Jr, Ross JS.

Diagn Mol Pathol. 1997 Aug;6(4):192-8.

PMID:
9360840
26.

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ.

Hum Pathol. 1997 Jul;28(7):827-33.

PMID:
9224752
27.

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.

Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD, Muraca PJ.

Cancer. 1997 Jun 1;79(11):2162-70.

PMID:
9179063
28.

Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.

Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS.

Cancer. 1996 Oct 1;78(7):1461-9.

PMID:
8839552
29.

Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?

Perrotti M, Kaufman RP Jr, Jennings TA, Thaler HT, Soloway SM, Rifkin MD, Fisher HA.

J Urol. 1996 Jul;156(1):106-9.

PMID:
8648768
30.

E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology.

Ross JS, Cheung C, Sheehan C, del Rosario AD, Bui HX, Fisher HA.

Diagn Cytopathol. 1996 Jun;14(4):310-5.

PMID:
8725130
31.

E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.

Ross JS, del Rosario AD, Figge HL, Sheehan C, Fisher HA, Bui HX.

Hum Pathol. 1995 Sep;26(9):940-4.

PMID:
7672793
32.

The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study Group.

Berger BM, Naadimuthu A, Boddy A, Fisher HA, McConnell JD, Milam D, Mobley D, Rajfer J.

J Urol. 1995 Sep;154(3):1060-4.

PMID:
7543598
33.
34.

Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer.

Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HA, Messing E, et al.

Clin Cancer Res. 1995 Jan;1(1):57-61.

35.

Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma.

Kallakury BV, Jennings TA, Ross JS, Breese K, Figge HL, Fisher HA, Figge J.

Diagn Mol Pathol. 1994 Dec;3(4):227-32.

PMID:
7532528
36.

Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.

Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD, Fisher HA.

Cancer. 1994 Nov 15;74(10):2811-8.

PMID:
7954242
37.

E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.

Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jennings TA, Ingle R, Kim DN.

Mod Pathol. 1994 Oct;7(8):835-41.

PMID:
7530850
38.

Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.

Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA.

Hum Pathol. 1994 Jan;25(1):92-7.

PMID:
7508886
39.

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.

Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HA.

Cancer. 1993 Nov 15;72(10):3020-8.

PMID:
8106140
40.

Management of penile carcinoma: the case for selective application of inguinal lymph node dissection in stages T1-T4.

Fisher HA.

Semin Urol. 1993 May;11(2):74-9. Review. No abstract available.

PMID:
8362123
41.

DNA ploidy of oncocytic-granular renal cell carcinomas and renal oncocytomas by image analysis.

Veloso JD, Solis OG, Barada JH, Fisher HA, Ross JS.

Arch Pathol Lab Med. 1992 Feb;116(2):154-8.

PMID:
1733409
42.

Prostatic carcinosarcoma: case report and review of literature.

Nazeer T, Barada JH, Fisher HA, Ross JS.

J Urol. 1991 Nov;146(5):1370-3. Review.

PMID:
1942296
43.

Verrucous carcinoma of the bladder.

Horner SA, Fisher HA, Barada JH, Eastman AY, Migliozzi J, Ross JS.

J Urol. 1991 Jun;145(6):1261-3. Review.

PMID:
2033707
44.

Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications.

Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna MG Jr, Pagano F, Alfthan O, Brosman S, Fisher HA, Jakse G, et al.

Prog Clin Biol Res. 1989;310:335-55. Review. No abstract available.

PMID:
2505273
45.

BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.

Fisher HA.

Prog Clin Biol Res. 1989;310:275-83. Review. No abstract available.

PMID:
2505271
46.

Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinoma.

Chang AY, Fisher HA, Spiers AS, Boros L.

J Interferon Res. 1986 Dec;6(6):713-5.

PMID:
3572090
48.

Nonoperative supravesical urinary diversion in obstetrics and gynecology.

Fisher HA, Bennet AH, Rivard DJ, Caputo T, Goldman M.

Gynecol Oncol. 1982 Dec;14(3):365-72. No abstract available.

PMID:
7152365
49.

The Unmarried Mother and Her Child.

Fisher L, Fisher HAL.

Hospital (Lond 1886). 1920 Dec 4;69(1800):228. No abstract available.

Supplemental Content

Loading ...
Support Center